OTCMKTS:INNV - Innovus Pharmaceuticals Stock Price, Forecast & News

Innovus Pharmaceuticals trades on the OTCMKTS under the ticker symbol "INNV."

Innovus Pharmaceuticals Inc (OTCMKTS:INNV) released its quarterly earnings results on Thursday, November, 14th. The company reported ($0.81) earnings per share (EPS) for the quarter, missing the Zacks' consensus estimate of ($0.41) by $0.40. The firm had revenue of $5.76 million for the quarter, compared to the consensus estimate of $7.25 million. Innovus Pharmaceuticals had a negative net margin of 35.85% and a negative return on equity of 1,611.96%. View Innovus Pharmaceuticals' Earnings History.

Innovus Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Monday, April 6th 2020. View Earnings Estimates for Innovus Pharmaceuticals.

1 brokerages have issued 12-month price objectives for Innovus Pharmaceuticals' shares. Their forecasts range from $5.00 to $5.00. On average, they anticipate Innovus Pharmaceuticals' stock price to reach $5.00 in the next year. This suggests a possible upside of 488.2% from the stock's current price. View Analyst Price Targets for Innovus Pharmaceuticals.

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Innovus Pharmaceuticals in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Innovus Pharmaceuticals.

Media headlines about INNV stock have trended somewhat negative on Monday, InfoTrie Sentiment reports. The research group ranks the sentiment of media coverage by monitoring more than six thousand news and blog sources. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Innovus Pharmaceuticals earned a media sentiment score of -1.4 on InfoTrie's scale. They also gave news stories about the company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an impact on the company's share price in the near future. View News Stories for Innovus Pharmaceuticals.

Some companies that are related to Innovus Pharmaceuticals include Tonix Pharmaceuticals (TNXP), Kaya (KAYS), Tetraphase Pharmaceuticals (TTPH), iCo Therapeutics (ICOTF), Pivot Pharmaceuticals (PVOTF), Rexahn Pharmaceuticals (REXN), Acura Pharmaceuticals (ACUR), Novus Therapeutics (NVUS), International Stem Cell (ISCO), Sonoma Pharmaceuticals (SNOA), Capricor Therapeutics (CAPR), Integrated BioPharma (INBP), Reliv International (RELV), Melinta Therapeutics (MLNT) and GT Biopharma (GTBP).

Based on aggregate information from My MarketBeat watchlists, some companies that other Innovus Pharmaceuticals investors own include EEStor (ESU), Antares Pharma (ATRS), The Medicines (MDCO), Federal National Mortgage Association (FNMA), Frontier Communications (FTR), FedEx (FDX), Republic First Bancorp (FRBK), NVIDIA (NVDA), Pacific Premier Bancorp (PPBI) and Prospect Capital (PSEC).

Shares of INNV can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of INNV stock can currently be purchased for approximately $0.85.

Innovus Pharmaceuticals has a market capitalization of $2.54 million and generates $23.99 million in revenue each year. The company earns $-8,280,000.00 in net income (profit) each year or ($4.16) on an earnings per share basis. Innovus Pharmaceuticals employs 27 workers across the globe.View Additional Information About Innovus Pharmaceuticals.

The official website for Innovus Pharmaceuticals is http://www.innovuspharma.com/.

Innovus Pharmaceuticals' mailing address is 8845 Rehco Road, San Diego CA, 92121. The company can be reached via phone at 858-964-5123 or via email at [email protected]